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2.1: DEFINITION AND IDENTIFICATION OF CKD
PROGRESSION
2.1.1: Assess GFR and albuminuria at least annually
in people with CKD. Assess GFR and
albuminuria more often for individuals at
higher risk of progression, and/ or where
measurement will impact therapeutic deci-
sions (Figure 17). (Not Graded)
RATIONALE
The statement is worded this way to remind the practitioner
to use both GFR and albuminuria in order to assess
progression and is consistent with the definition offered in
Chapter 1 regarding definitions of CKD which include both
parameters. There is increasing evidence which supports that
both parameters are valuable. Lower GFR and greater
albuminuria are both associated with an increased rate of
progression and are synergistic.
More frequent measures of eGFR and albuminuria should be
considered in patients with a lower GFR and greater
albuminuria as these people are more likely to progress.
Frequency of measurement should also be individualized based
on the patient history and underlying cause of kidney disease.
In specific conditions (e.g., GN or increased levels of
albuminuria), frequent (every 1–3 months) assessment may
guide therapeutic decisions. Regular monitoring of stable
patients may include more frequent monitoring than
annually, but will be dictated by underlying cause, history,
and estimates of GFR and ACR values obtained previously.
Evidence Base
There is variability in the presence of or rate of decline
of kidney function in those with CKD. The rate at which
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Figure 17 |GFR and albuminuria grid to reflect the risk of progression by intensity of coloring (green, yellow, orange, red, deep
red). The numbers in the boxes are a guide to the frequency of monitoring (number of times per year). Green reflects stable disease, with
follow-up measurements annually if CKD is present; yellow requires caution and measurements at least once per year; orange requires
measurements twice per year; red requires measurements at 3 times per year while deep red may require closest monitoring approximately
4 times or more per year (at least every 1–-3 months). These are general parameters only based on expert opinion and must take into
account underlying comorbid conditions and disease state, as well as the likelihood of impacting a change in management for any
individual patient. CKD, chronic kidney disease; GFR, glomerular filtration rate. Modified with permission from Macmillan Publishers Ltd:
Kidney International. Levey AS, de Jong PE, Coresh J, et al.30 The definition, classification, and prognosis of chronic kidney disease: a KDIGO
controversies conference report. Kidney Int 2011; 80: 17–28; accessed http://www.nature.com/ki/journal/v80/n1/full/ki2010483a.html
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this decline occurs also varies based on the underlying
population, cause of CKD, presence of albuminuria/protein-
uria, comorbidities and age. The Work Group searched the
literature for longitudinal studies that evaluated decline
in kidney function. As outlined in Table 20 the study
populations included healthy adults, those with comorbidity,
as well as a subgroup of adults aged 65 and older.
Data from the PREVEND study, a prospective, popula-
tion-based cohort study, provides important information
on decline in kidney function at the population level.219
The PREVEND study evaluated 6894 people over a 4-year
period and reported loss in eGFR of 2.3ml/min/1.73m2/
4 years in the whole population, 7.2ml/min/1.73m2/4 years
in participants with macroalbuminuria (4300mg/24 hours)
and 0.2ml/min/1.73 m2/4 year in participants with impaired
renal function. The yearly decline in eGFR among a Japanese
general population over 10 years was slightly lower at
0.36ml/min/1.73 m2/year.220 The rate of eGFR decline was
approximately two times higher in participants with
proteinuria, and about 1.5 times higher among participants
with hypertension.220 Among adults aged 65 and older,
progression (median follow-up 2 years) varied by sex and
presence of diabetes.223 In general these studies suggest
progression rates of approximately 0.3 to 1ml/min/1.73m2/
year among participants without proteinuria or comor-
bidity and rates of approximately two to three times higher
among participants with proteinuria or comorbidity. The
somewhat surprising finding that eGFR had low rates of
progression among the group with impaired renal function
at baseline219 has been shown in other studies225 and may
relate to the statistical phenomenon of regression to the
mean. There is also a concern that it is hard to maintain
consistent calibration of the SCr assay over time and
progression results are highly sensitive to drift in the
creatinine assay.
Studies evaluating rate of decline in eGFR among
populations with CKD specifically are outlined in Table 21
and typically demonstrate a slightly more rapid rate of
decline in this subgroup, thus requiring more frequent
assessment of GFR and albuminuria.
Data from the MDRD Study during a mean 2.2 year
follow-up showed that the average rate of decline in GFR
ranged from 2.3 to 4.5ml/min/year, depending on the
baseline GFR and protein/MAP treatment assignments.227
Similarly, a more recent study of 4231 patients with GFR
categories G3a-G5 (GFRo60 ml/min/1.73m2) referred to a
nephrologist showed a mean decline in GFR of 2.65ml/min/
1.73m2/year,231 and variability in the rates of decline in this
referred cohort.
Note that there have been no studies which evaluate the
utility of more or less frequent monitoring in CKD cohorts.
International Relevance
Frequency of measurements of GFR and albuminuria may
vary by country and so are economic resources available
to support such testing, and the ability to implement
therapeutic strategies to address changes. Nonetheless, given
the availability of simple monitoring tools like urine reagent
Table 20 | Decline in kidney function in various populations (longitudinal studies only)
Reference Population N GFR decline
Healthy
Slack TK216 Healthy kidney donors 141 0.40ml/min/year
Rowe JW et al.217 Healthy males 293 0.90ml/min/1.73 m2/year (CrCl)
Lindeman RD218 Healthy males 254 0.75ml/min/year (CrCl)
Halbesma N et al.219 PREVEND cohort (all participants) 6894 0.55ml/min/1.73 m2/year
Imai E et al.220 Annual health exam participants in Japan 120,727 0.36ml/min/1.73 m2/year
Matsuchita K et al.221 Atherosclerosis Risk In Communities Cohort 13,029 0.47%/year (median)
Kronborg J et al.222 Healthy adults from Norway 4441 1.21ml/min/1.73 m2/year (men)
1.19ml/min/1.73 m2/year (women)
With comorbidity
Lindeman RD218 Males with renal/urinary tract disease 118 1.10ml/min/year (CrCl)
Lindeman RD218 Males with hypertension 74 0.92ml/min/year (CrCl)
Halbesma N et al.219 PREVEND cohort – adults with macroalbuminuria (4300mg/24 hours) 86 1.71ml/min/1.73 m2/year
Halbesma N et al.219 PREVEND cohort - Adults with impaired renal function
(5% lowest CrCl/MDRD GFR)
68 0.05ml/min/1.73 m2/year
Imai E et al.220 Annual health exam participants in Japan with hypertension 16,722 0.3 to 0.5ml/min/1.73 m2/year
Imai E et al.220 Annual health exam participants in Japan with proteinuria
(X1+ dipstick proteinuria)
2054 0.6 to 0.9ml/min/1.73 m2/year
Older adults
Hemmelgarn B et al.223 Males age 465 with diabetes 490 2.7ml/min/1.73 m2/year
Hemmelgarn B et al.223 Males age 465 without diabetes 2475 1.4ml/min/1.73 m2/year
Hemmelgarn B et al.223 Females age 465 with diabetes 445 2.1ml/min/1.73 m2/year
Hemmelgarn B et al.223 Females age 465 without diabetes 3163 0.8ml/min/1.73 m2/year
Keller C et al.224 Cardiovascular Health Study 4128 1.83ml/min/1.73 m2/year (based on
cystatin C-based eGFR)
Abbreviations: CrCl, creatinine clearance; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; PREVEND, Prevention of Renal and Vascular End-Stage
Disease.
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strips, consideration may be given to implementation of this
assessment in high-risk groups.
Implications for Clinical Practice and Public Policy
Practitioners must incorporate underlying category of
GFR and albuminuria as well as cause of kidney disease
and individual patient characteristics in determining the
frequency of ongoing assessment. The implications for
practice include the incorporation of regular monitoring
of both GFR and albuminuria into clinical care for patients
with CKD.
There are no immediate implications for public policy of
this statement.
Areas of Controversy, Confusion, or Non-consensus
There are many who would like more definitive guidance on
frequency of measurement according to specific categories of
risk. However this is not possible at the current time given
the lack of evidence to guide such statements and the extreme
number of individual circumstances that would mitigate any
proposed protocol.
We recommend further research to more accurately define
the frequency with which GFR and albuminuria measure-
ments should be performed based on their ability to inform
strategies which prevent adverse outcomes (e.g., progression
of kidney disease and death).
Clarification of Issues and Key Points
a) Assessment of both GFR and albuminuria should be
undertaken to evaluate progression.
b) More frequent assessment is required as kidney disease
progresses.
c) Not all individuals with CKD require close surveillance
and monitoring; clinical context remains an important
modifier for all recommendations.
d) While cause of CKD is an important predictor of
progression, it is the values of GFR and albuminuria
that are used to assess progression.
Pediatric Considerations
Currently there is no evidence as to the value of increasing the
frequency of assessment of either GFR or proteinuria in
children with CKD. Eventually more complete longitudinal
data from the CKiD cohort55 and hence better granularity of
individual and group rates of decline in GFR may provide the
data required to strengthen proof of this guideline in children.
Table 21 | Decline in kidney function in CKD populations
Study Study population N
Baseline GFR
ml/min/1.73 m2
Mean Follow-up
years
GFR decline
Mean (SD) or
(95% CI) ml/min/1.73 m2/year
MDRD Study
Group226
Study A: GFR 25-80ml/min/1.73 m2 28 Mean (SD)
37.1 (8.7)
1.2 3.7 (7.6)
Study B: GFR 7.5-24ml/min/1.73 m2 63 15.0 (4.5) 4.3 (4.7)
Klahr S et al.227 Study 1: GFR 25-55ml/min/1.73 m2 Mean (SD) 2.2 years
- Usual protein, usual MAP 145 37.6 (9.0) 4.5 (3.7 – 5.3)
- Usual protein, low MAP 149 38.2 (8.6) 3.3 (2.5 – 4.1)
- Low protein, usual MAP 140 38.9 (8.8) 3.3 (2.5 – 4.2)
- Low protein, low MAP 151 39.7 (9.1) 2.3 (1.5 – 3.0)
Study 2: GFR 13-45ml/min/1.73 m2
- Low protein, usual MAP 62 18.7 (3.1) 4.9 (3.8 – 5.9)
- Low protein, low MAP 67 18.8 (3.3) 3.9 (3.2 – 4.7)
- Very low protein, usual MAP 61 18.3 (3.7) 3.6 (2.8 – 4.4)
- Very low protein, low MAP 65 18.4 (3.5) 3.5 (2.6 – 4.5)
Wright J et al.228 African Americans with
hypertension and
GFR 20-65 ml/min/1.73m2
Mean (SD) 4 years Mean (SE)
- Low MAP 380 46.0 (12.9) 2.21 (0.17)
- Usual MAP 374 45.3 (13.2) 1.95 (0.17)
Eriksen B229 GFR categories G3a and G3b
(GFR 30–59 ml/min/1.73 m2)
3047 Median (IQR)
55.1 (50.8 – 57.9)
Median 3.7 years Mean
1.03ml/min/1.73m2/year
Jones C et al.230 Nephrology referrals with
GFR categories G3a-G5
(GFRo60 ml/min/1.73 m2)
726 Median (IQR)
29 (18-38)
Median (IQR)
2.9 years (1.3 – 4.1)
Median
0.35ml/min/1.73m2/year
Levin A et al.231 Nephrology referrals with
GFR categories G3a-G5
(GFRo60 ml/min/1.73 m2)
4231 Median
33ml/min/1.73m2
Median (IQR)
2.6 years
(1.6-3.6)
Mean
2.65ml/min/1.73m2/year
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; GFR, glomerular filtration rate; IQR, interquartile range; MAP, mean arterial pressure; MDRD, Modification of
Diet in Renal Disease; SD, standard deviation; SE, standard error.
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As described in detail in the Pediatric Considerations for
Recommendation 1.3.1, there is good observational evi-
dence acknowledging the importance of level of GFR and
proteinuria at baseline on predicting rates of progression and
it may be that interventional opportunities would exist if
closer monitoring and earlier recognition of worsening in
these values for the individual were available. Future studies
may examine this.
2.1.2: Recognize that small fluctuations in GFR are
common and are not necessarily indicative of
progression. (Not Graded)
2.1.3: Define CKD progression based on one of more of
the following (Not Graded):
K Decline in GFR category (Z90 [G1], 60-89
[G2], 45-59 [G3a], 30-44 [G3b], 15-29 [G4],
o15 [G5]ml/min/1.73 m2). A certain drop in
eGFR is defined as a drop in GFR category
accompanied by a 25% or greater drop in eGFR
from baseline.
K Rapid progression is defined as a sustained decline
in eGFR of more than 5ml/min/1.73 m2/year.
K The confidence in assessing progression is
increased with increasing number of serum
creatinine measurements and duration of
follow-up.
RATIONALE
This statement serves to inform clinicians that some consistent
definition of progression is required and should be imple-
mented based on an appreciation of baseline values for an
individual. There is considerable controversy as to what
constitutes normal progression of CKD. The potential for
biological and analytical variation associated with use of SCr
measurements should be taken into account as they represent
reversible fluctuations in GFR and are not necessarily
indicative of progression. Further, it is important to recognize
that the degree of precision with which progression is able to
be estimated is highly dependent upon two factors: the
number of SCr measurements used to define progression and
the duration of follow-up. Estimating risk of ESRD based on
extrapolation of the previous rate of change in GFR required
substantial information (Z4 measurements over Z3 years
in most cases) to add to the risk information in the most
recent GFR. Further, it should be recognized that some
reno-protective treatments (e.g., BP lowering and RAAS
antagonists) result in a slower rate of GFR decline long-
term but often lower GFR in a stepwise fashion as a result of
hemodynamic effects. Even substantial (5-25%) reductions in
GFR may be protective, complicating the interpretation of
progression in these individuals. Finally, underlying disease
activity should be considered when assessing patients for
progression of kidney dysfunction.
The importance of determining the rate of decline in
kidney function over time is to identify individuals who are
progressing at a more rapid rate than anticipated, which is
associated with increased morbidity and mortality. Indivi-
duals who are ‘‘rapid progressors’’ should be targeted to
slow their progression and associated adverse outcomes.
A progressive decline in kidney function is influenced by
baseline GFR category and albuminuria category.
Evidence Base
Unfortunately few studies are available to guide us regarding
the optimal definition of ‘‘rapid progression.’’ Such studies
require serial follow-up of patients to calculate change in
GFR over time, with more frequent measurements and longer
duration of follow-up providing more accurate estimates.
The Work Group reviewed cohort studies of the general
population that have evaluated rapid progression of kidney
function (Table 22).
Approaches to define decline in kidney function included
absolute rate of loss232,233,235 as well as percent change.221,234
Studies consistently demonstrate that a more rapid rate of
loss of kidney function was associated with an increased risk
of adverse clinical outcomes including death and vascular
related events. These studies have been limited however by
relatively few patients with GFR levelso60 ml/min/1.73 m2,
few measurements of SCr, and relatively short duration of
follow-up to obtain accurate estimates of the rate of decline
in kidney function. The precision of the estimate of the slope
depends on a number of factors including the number of
measurements of kidney function, biological variability,
measurement error, and duration of follow-up. In general
at least three measures of kidney function are required to
permit an estimate of slope.1
None of these studies assessed the impact of albuminuria
on rate of ‘‘rapid decline’’ in kidney function. However as
noted in Recommendation 2.1.1, the presence of proteinuria
has been associated with a faster rate of kidney function
decline compared with people without proteinuria.236–238
Two of the largest prospective cohort studies have shown an
approximate two-fold increase in the rate of decline in GFR
in the presence of proteinuria.219,220 Further evidence
regarding the potential adverse effects of albuminuria on
outcomes has been reported among patients with diabetes.
The AER is one of the best indicators of diabetic nephropathy
risk in both type 1 and type 2 diabetes, and patients with
microalbuminuria have been reported to have 200 to 400%
higher risk for progression to proteinuria than patients with
normal albuminuria.239,240 Long-term follow-up studies have
also demonstrated the increased risk of ESRD associated with
albuminuria among patients with both type 1 and type 2
diabetes.241,242
Given the recognized limitations in defining rapid
progression, the Work Group aimed to provide options for
determination of progression, based on their clinical utility,
and ease of use. One approach included an assessment of
change in GFR category, combined with a minimal percent
change. A criterion requiring both a change in GFR category
(e.g., change from G2 to G3a) and percent change would
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ensure that small changes GFR from 61 to 59ml/min/1.73 m2
for example, which represents a change in category but a
minimal change in GFR, would not be misinterpreted to
represent progression. A change of o25% in a pair of GFR
estimates may reflect physiologic variation rather than true
progression.
Additional work to inform this definition has been
undertaken, using data from the Alberta Kidney Disease
Network (AKDN).243 In this analysis 598,397 adults with at
least two out-patient measures of SCr spaced at least 6
months apart were included. Progression was defined as
‘‘certain’’ (rise or drop) if during the median follow-up time
of 2.4 years there was a change in GFR category combined
with a 25% or greater change in GFR from the baseline
measurement (constituting a certain rise or a certain drop).
Participants who changed GFR category but did not meet the
criterion of 25% change in GFR were categorized as
‘‘uncertain’’ rise or drop. The reference group was comprised
of participants who did not change GFR category over the
follow-up period. As outlined in Table 23, compared to
participants with stable eGFR, those with a certain drop had
an almost two-fold increase in the risk of all-cause mortality
(HR 1.89; 95% CI 1.83–1.95)244 and a five-fold increase in the
risk of ESRD (HR 5.11; 95% CI 4.56–5.71).245 Lesser degree
of risk was present for those with an uncertain drop
(reflecting a change in category only). It is worth noting
that once progression occurs, the last eGFR which has a lower
level often contains much of the information about risk of
ESRD and extrapolation of progression using information
from prior progression and the most recent eGFR is only
useful if the information about progression is precise and the
patient’s trajectory is linear.
The second approach to define progression takes into
account the rate of change in kidney function based on a
slope analysis. In this approach the rate of loss is defined by
both the absolute rate of change and the percent change, as
determined among a cohort of 529,312 adults who had at
least 3 outpatient SCr measurements over a four year period
(AKDN databases). Two indices of change in eGFR were
estimated: the absolute annual rate of change (categorized as:
increase, stable and -1, -2, -3, -4, and Z -5ml/min/1.73 m2/
year decline); and the annual percentage change (categorized
as: increase, stable, -1 to -2, -3 to -4, -5 to -6, and Z-7
percent decline/year). The adjusted ESRD risk associated
with each category of change in eGFR was estimated, using
stable eGFR (no change in eGFR) as the reference. The results
were adjusted in two ways: for eGFR and covariates at the
time of the first eGFR measurement, and at the time of the
last eGFR measurement. As outlined in Table 24, the risk of
ESRD increased almost two-fold for every 1ml/yr decline in
eGFR, when adjusted for covariates and eGFR at the time of
the first eGFR measurement. The risk remained significant,
but was less pronounced, when adjustments were performed
at the time of the last eGFR measurement. This suggests
that extrapolation of kidney function beyond the last
measurement of eGFR is still informative, but identifies a
lesser risk. Similar results were obtained when change in
eGFR was defined by a percentage.
Table 23 | CKD progression and risk of all-cause mortality and
ESRD using baseline (first) eGFR
Definition of
progression
All-cause mortality
HR** (95% CI)
ESRD*
HR** (95% CI)
Certain rise 1.51 (1.46–1.56) 0.33 (0.26–0.42)
Uncertain rise 1.12 (1.08–1.16) 0.39 (0.30–0.51)
Stable (reference) Ref Ref
Uncertain drop 0.98 (0.95–1.01) 2.13 (1.84–2.47)
Certain drop 1.89 (1.83–1.95) 5.11 (4.56–5.71)
Abbreviations: CI, confidence interval; eGFR, glomerular filtration rate; ESRD, end-
stage renal disease; HR, hazard ratio.
Data from Turin et al.244,245
*ESRD defined as requiring renal replacement therapy.
**Adjusted for age, gender, hypertension, diabetes, proteinuria, Charlson comor-
bidities and baseline (first) eGFR.
Table 24 | Association between absolute and percentage change in kidney function and risk of ESRD*, based on adjustment for
eGFR at the first and last measurement
Absolute rate of change
(over a median of 3.5 years)
Adjusted for eGFR at first
creatinine measurement HR** (95% CI)
Adjusted eGFR at last creatinine
measurement HR** (95% CI)
Increasing eGFR 0.64 (0.48–0.86) 1.20 (0.90–1.61)
Stable (0ml/min/1.73 m2/year) Ref Ref
-1ml/min/1.73 m2/year 2.05 (1.56–2.69) 1.45 (1.11–1.90)
-2ml/min/1.73 m2/year 2.71 (2.08–3.53) 1.58 (1.21–2.06)
-3ml/min/1.73 m2/year 3.98 (3.06–5.17) 1.63 (1.25–2.13)
-4ml/min/1.73 m2/year 5.82 (4.45–7.61) 1.90 (1.45–2.48)
-5ml/min/1.73 m2/year or more 12.49 (10.04–15.53) 1.70 (1.36–2.12)
Percentage Change:
Increasing 0.76 (0.55–1.07) 1.11 (0.80 – 1.55)
Stable Ref Ref
-1 to -2%/year 1.17 (0.81–1.68) 0.97 (0.67–1.40)
-3 to -4%/year 1.79 (1.25–2.56) 1.19 (0.83–1.71)
-5 to -6%/year 2.26 (1.55–3.29) 1.21 (0.83–1.78)
-7%/year or more 11.30 (8.53–14.97) 2.17 (1.60–2.93)
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; ESRD, end-stge renal disease; HR, hazard ratio.
Data from the Alberta Kidney Disease Network.
*ESRD defined as requiring renal replacement therapy.
**Adjusted for age, gender hypertension, diabetes, proteinuria, Charlson comorbidities and eGFR at the first or last measurement.
68 Kidney International Supplements (2013) 3, 63–72
chapte r 2
With respect to the impact of changes in albuminuria over
time, a study from the Ongoing Telmisartan Alone and in
Combination with Ramipril Global Endpoint trial (ONTAR-
GET) investigators showed that a greater than or equal to
twofold increase in albuminuria from baseline to 2 years
associated with a nearly 50% higher mortality (HR 1.48; CI
1.32-1.66), while a greater than or equal to twofold decrease
in albuminuria associated with 15% lower mortality (HR
0.85; CI 0.74-0.98) compared with those with lesser changes
in albuminuria, after adjustment for baseline albuminuria,
BP, and other potential confounders. Increases in albuminur-
ia also significantly associated with renal outcomes, defined
as ESRD or doubling of SCr (HR 1.40; CI 1.11-1.78), while a
decrease in albuminuria was associated with a decrease of the
combined renal outcome (HR 0.73; CI 0.57-0.95).246
However, preliminary analysis of cohort studies is limited
and suggests that further research is required to more
accurately determine the change in albuminuria associated
with an increased risk of kidney disease progression.
There is accumulating evidence that the trajectories of
GFR decline are non-linear, and may take a number of
different courses over time. The longer an individual is
followed over time, the more likely they are to experience
non-linear change in trajectory.247,248 The non-linearity
of a trajectory may be due to intercurrent illness, changes
in medication, intrinsic to the disease process, or any
combination of these factors. Li et al.247 described individual
GFR progression trajectories over twelve years of follow-up
among participants in the African American Study of Kidney
Disease (AASK) (Figure 18). The authors reported that
41.6% of patients exhibited a greater than 90% probability
of having a non-linear trajectory; in 66.1% the probability of
non-linearity was 450%.
International Relevance
Studies to date evaluating rapid progression of kidney disease
have been limited to North American (White and African
American), European, and Asian populations. Given the
differences in the prevalence of CKD by ethnic group, there
may also be variations in rate of progression by ethnicity, and
in particular ethnic groups with high rates of comorbid
conditions leading to ESRD such as the Aboriginal popula-
tion. Thus, the definition of rapid progression may vary
according to country or region. However, by using a general
definition of progression, which includes change of category
of eGFR or albuminuria or both, as well as a numeric change
over an established period of time, we believe that the
definition of progression can be used in all cohorts.
Implications for Clinical Practice and Public Policy
Practitioners should monitor the GFR and albuminuria at
regular intervals to identify rates of decline which exceed that
normally demonstrated. The rate of GFR decline may be
relatively constant over time in an individual; however the
rate of GFR decline is highly variable among people and over
long periods of observation, within individuals. Thus
clinicians are encouraged to evaluate changes in GFR or
albuminuria in the context of multiple observations over
time, and with attention to clinical events which may have
impacted the change. A number of factors influence
assessment of rate of progression including frequency and
duration of GFR and albuminuria measurements as well as
Figure 18 |Distribution of the probability of nonlinearity (top) with three example trajectories demonstrating different
probabilities of nonlinearity (bottom). Reprinted from Li L, Astor BC, Lewis J, et al. Longitudinal Progression Trajectory of GFR
Among Patients With CKD. Am J Kidney Dis 2012; 59: 504-512 with permission from the National Kidney Foundation.247; accessed
http://download.journals.elsevierhealth.com/pdfs/journals/0272-6386/PIIS0272638611017896.pdf
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factors related to the patient (e.g., baseline GFR, comor-
bidities, age etc.).
There are no implications for public policy at this time.
Areas of Controversy, Confusion, or Non-consensus
The practical issue in clinical practice and clinical trials is
how to define progression (as inferring true deterioration in
kidney function) with meaningful thresholds that are easy
to understand for the non-nephrologist. While changes in
proteinuria may signify change in clinical condition, there are
no data yet to suggest that change in proteinuria is itself
reliably associated with progression of CKD per se. This may
be confusing to practitioners, since a change in quantity of
proteinuria is an indication for referral.
We recommend research to confirm rates which can be
classified as slow, moderate, and rapid progression of kidney
disease. The rate to define ‘‘rapid progression’’ may vary
depending on the outcome considered, such as kidney failure
versus mortality for example. It will be important for
researchers to determine methods by which reproducible
classification systems for describing rates of progression can
be developed. There are increasing data to suggest the non-
linearity of progressive disease in many individuals. This
makes extrapolation risky and warrants continued assessment
of the slope on a regular basis.
Clarification of Issues and Key Points
Small fluctuations in GFR are common and should not be
misinterpreted to represent progressive decline in kidney
function. Many factors can cause a small change in GFR
including medications, volume status, measurement error,
and biological variability. Assessment of progressive decline
in GFR needs to take into account the number of
measurements considered and time period of assessment.
In pediatrics, information about utilty of serial creatinine
measurements over periods of time during which growth
(and muscle mass increase) is occurring, for the diagnosis of
progression or regression, remains problematic.
Pediatric Considerations
Applying strict GFR criteria in order to develop cutoff values
associated with ‘true’ progression in terms of any one
individual child is not currently possible. Conceptually the
movement from various levels of renal function downward,
in particular if that movement is associated with increasing
comorbidities or intensity of such, is a reasonable approach.
The most informative data available in children comes from
the longitudinal GFR data from CKiD.72 Examination of the
whole cohort reveals an annual decline in GFR of 4.2%;
median GFR decline was 1.8ml/min/1.73 m2 (interquartile
range [IQR] 6.6 to 1.6); this can be expressed as a median
absolute decline in GFR of 4.3ml/min/1.73 m2 (IQR 11.9 to
1.1) and 1.5ml/min/1.73 m2 (IQR 5.0 to1.8).
Given that the lower IQR in each of the overall cohort and
both sub-groups is equal to or exceeds the suggested decline
of 5ml/min/1.73 m2 as stated here, we suggest that it is
reasonable to adopt this definition at least for the purpose of
classification as it relates to ‘rapid’ progression; note the
above values all relate to measured GFR.
Increasing numbers of any given measurement of an event
generally allow for greater precision and accuracy. However,
the simple repeated measurements of creatinine over time are
less likely to be valuable in children than in adults with CKD.
Unlike adults with static muscle mass and hence expected
stability in creatinine values, or adults with expected
declining muscle mass and hence expectations of declining
creatinine if renal function has remained stable, pediatric
populations have a situation of increasing muscle mass with
expectation of increasing creatinine in the otherwise normal
child without CKD. In a child with CKD who is growing
therefore, and in particular one going through puberty, the
simple comparison of creatinine values over time will likely
not be sufficient to presume CKD progression or regression
has occurred. The two exceptions to this would be a) a series
of creatinine measurements demonstrating significant
increase over a short period of time wherein there is no
demonstrable or expected gain of muscle mass; b) values of
creatinine that over time demonstrate an increase to levels
above that which is expected of the child’s age and sex based
on population normative value for the lab and method of
measurement.
2.1.4: In people with CKD progression, as defined in
Recommendation 2.1.3, review current manage-
ment, examine for reversible causes of progression,
and consider referral to a specialist. (Not Graded)
RATIONALE
This statement intends to reassure patients and practitioners
that not all patients necessarily require referral to specialists,
but that this should be considered in the event that the
patient or clinician requires further guidance or prognostic
information. CKD progression, contextualized for the
individual circumstance, does not always require referral,
and earlier guidelines may not have been so overt in stating
this. Faster or unusual trajectories of progression should alert
the patient and physician to assess for potentially reversible
causes of progression.
Progressive kidney disease requires the need for more
aggressive assessment and treatment, which may include
referral to a nephrologist or specialist (if they are not
currently being managed by a nephrologist).
Evidence Base
Decline in GFR may not be constant, with acute decline
superimposed on CKD (see Chapter 2.2 for discussion of
factors associated with progression of a more chronic
nature). The most common risk factors identified for acute
decline in GFR for patients with established CKD include:
obstruction of the urinary tract; volume depletion; nonster-
oidal anti-inflammatory drugs (NSAIDs), including cyclo-
oxygenase-2 (COX 2) inhibitors; select antimicrobial agents
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such as aminoglycosides and amphotericin B; radiocontrast
agents; and angiotensin-converting enzyme inhibitors
(ACE-Is) and angiotensin-receptor blockers (ARBs).249–252
Readers are also referred to the KDIGO Clinical Practice
Guideline for Acute Kidney Injury7 which contains additional
relevant details regarding risk factors for rapid progression
and management strategies.
Rapid sustained decline in GFR could also be considered
an indication for referral once potentially reversible factors as
outlined above have been assessed and treated. The principles
guiding referral include additional input from a nephrologist
into management of CKD and preparation for RRT, such as
that which may be required with rapidly declining GFR. The
NICE guidelines for CKD also recommend referral for
‘‘rapidly declining GFR’’ although the definition of rapidly
declining is not provided.186 Most studies assessing nephrol-
ogy referral have focused on early versus late referral, and not
considered the impact or implications of nephrology referral
in situations associated with rapid decline in GFR.253 The
evidence that such referral will change outcomes is not clear
but given that nephrologists often have access to education
and specialized services, which are essential for optimal
preparation for RRT, referral to a specialist is recommended.
Additional discussion of when to consider a referral to a
nephrologist can be found in Chapter 5.
International Relevance
Risk factors for acute deterioration in kidney function may vary
slightly by country of origin, although the common categories
in general (e.g., medications, volume depletion and urinary
tract obstruction) would be relevant irrespective of country.
This set of statements serves to ensure that attention to changes
in kidney function in those identified with kidney disease is part
of the usual care of these individuals.
Implications for Clinical Practice and Public Policy
Practitioners should be aware of the common risk factors for
acute-on-chronic kidney disease resulting in a rapid loss of
kidney function. Acute rapid deterioration in kidney function
should alert the practitioner to assess for these potentially
reversible causes of progression. This assessment would include
an evaluation for potential urinary tract obstruction as well as a
volume assessment and detailed medication review.
Areas of Controversy, Confusion, or Non-consensus
Readers are referred to the KDIGO Clinical Practice Guideline
for Acute Kidney Injury7 for a detailed discussion of issues
related to definition, diagnosis, and treatment of rapid
progression of kidney dysfunction, as defined by AKI.
Clarification of Issues and Key Points
There are no specific numeric values to define ‘‘rapid loss’’ as
this varies within and between disease states, individuals, and
populations. The key point for practitioners is to serially
review individual trajectories of changes in kidney function
so as to determine stability or not, identify changes in
previous stable trajectories, and to be aware of the
importance of circumstances where AKI changes the course
of CKD. Further studies are required to determine the rate of
loss of GFR that constitutes rapid loss of kidney function. In
children, interpretation of serial changes in SCr requires
understanding of normative value ranges and drivers of
change in SCr which are different than in adults.
2.2: PREDICTORS OF PROGRESSION
2.2.1: Identify factors associated with CKD progres-
sion to inform prognosis. These include cause of
CKD, level of GFR, level of albuminuria, age,
sex, race/ethnicity, elevated BP, hyperglycemia,
dyslipidemia, smoking, obesity, history of
cardiovascular disease, ongoing exposure to
nephrotoxic agents, and others. (Not Graded)
RATIONALE
The rationale for estimating the risk of kidney failure is that
it may inform referral, care plans, and other therapeutic
strategies, including frequency of monitoring and follow-up.
Previous guidelines have not been able to suggest risk
equations or relative and absolute risks of specific outcomes
but with the data currently available, this is now possible.
There are several factors that influence the likelihood and rate
of CKD progression including GFR and albuminuria category,
the degree of albuminuria, the cause of kidney disease, on-
going exposure to nephrotoxic agents, obesity, hypertension,
age, race/ethnicity and laboratory parameters such as Hb
(hemoglobin), albumin, calcium, phosphate, and bicarbonate.
As some of these risk factors are modifiable they should be
actively identified and, if present, be treated as they may
impact long-term outcomes including cardiovascular condi-
tions, QOL, and progression of CKD.
It is not yet clear what the relative weight of each of these
factors is in predicting in an individual whether he/she will
have progressive CKD.
Evidence Base
As progression of CKD is defined as either a progressive
decrease in GFR or a progressive increase in albuminuria, we
should consider separately whether different factors would
predict these two components of CKD differently. Given the
limited evidence, this will not be discussed separately. It is
however clear that a subject with a lower GFR to start with
will progress more rapidly to a GFR o15ml/min/1.73 m2,
just as a subject with already elevated albuminuria will
progress more rapidly to an ACR 4300mg/g (430mg/
mmol). Similarly, it is well-known that a subject with
membranous glomerulopathy is more likely to progress to
nephrotic syndrome, while a subject with adult polycystic
kidney disease is more likely to progress to ESRD.
Although there are many cross-sectional studies that describe
factors associated with a low GFR and factors associated with a
high albuminuria, the number of studies evaluating which
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factors are associated with progressive decreases in GFR and
progressive increases in albuminuria are more limited. In
general, it can be argued that most of the above-mentioned
factors are associated with a more progressive rise in albuminuria
and a more progressive fall in GFR. Most recently, studies have
focused on the development of risk scores for identifying
progressive decreases in GFR and progressive increases in
albuminuria. It has not yet been established which prediction
formula could best be used. Some formulas use just simple
demographic and clinical measures, while others also include
laboratory tests. Some were developed for high-risk populations,
such as people with known underlying CVD,254 with CKD in
general,255 or with specific causes of CKD, such as IgA
nephropathy,256 diabetic nephropathy,257 or renal artery steno-
sis.258 Others developed a risk prediction model in the general
population.259 This latter model included age, race, gender, and
in dichotomized version, the presence of anemia, hypertension,
diabetes, and CVD history. More recently, two studies used more
accurate laboratory parameters in addition to demographic
characteristics. The first study was in patients with an eGFR of
15-60ml/min/1.73 m2/year, and included age, gender, eGFR,
albuminuria, and serum calcium, phosphate, bicarbonate and
albumin.260 The second study was in subjects from the general
population and included age, eGFR, albuminuria, measured
levels of BP and C-reactive protein (CRP).261 The results from
these predictive models require validation in future studies but
they demonstrate the potential and the capabilities of developing
clinically meaningful classification of risk for individual patients.
Further research is required to establish whether prediction
formulas may differ for different ethnicities.
International Relevance
Studies describing factors associated with lower GFR and
higher ACR have been described from all over the world. In
general, there is much overlap between these data. It may be
that in different parts of the world the relative weight of each
of the factors predicting progressive increases in albuminuria
or decreases in GFR may substantially differ.
Implications for Clinical Practice and Public Policy
It is important to realize that some factors predicting
progression of CKD are modifiable. This holds true for
lifestyle measures such as cessation of smoking and preven-
tion of obesity. It also subtends to lowering of BP, lowering of
albuminuria and prevention of hyperglycemia. A further
factor that may be modifiable is the underlying cause of
CKD. As various causes may respond to targeted treatment,
finding the cause of CKD is the starting point of the work-up
of a subject with CKD. If this causal disease is modifiable, for
example by immunosuppressive treatment, then such
treatment is the first step to consider. Management of
patients with CKD and delay of progression are dealt with in
Chapter 3 and more fully in other guidelines (see KDIGO
Clinical Practice Guideline for Glomerulonephritis8 and
KDOQI Clinical Practice Guideline for Diabetes and CKD:
2012 Update.262)
Areas of Controversy, Confusion, or Non-consensus
While there are prediction equations available using combina-
tions of eGFR, albuminuria, cause of CKD, and some or all of
the laboratory abnormalities listed, they have not been used in
clinical practice to guide therapy as yet. Furthermore, while the
associated abnormalities clearly increase in severity with
worsening kidney function, normalizing them in some instances
has not changed progression to ESRD. The need for prediction
equations to take into account changes over time (trajectories)
and stability or instability of specific factors has been raised by
many. Nonetheless, the ability to determine progression versus
stability should be of value for patients and clinicians.
Clarification of Issues and Key Points
Clinicians should attempt to determine stability or progres-
sion of patients with CKD for the purposes of informing care.
Further research is required to determine which formula best
predicts who will have progressive increases in albuminuria
and progressive decreases in GFR. The key components of
prediction equations for ESRD may well be different than
prediction equations for cardiovascular events or death.
Pediatric Considerations
A more complete discussion of the evidence in children
supporting these factors as potentially related to risk of
progression, in addition to the pediatric specific risk of
growth/puberty, can be found in the Pediatric Considerations
for Recommendation 1.3.1.
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